Kidney Transplant. Kidney transplant status
Conditions
Interventions
Intervention 1: The trial group will be administered oral melatonin at the dose of 3mg/day for a period of 28 days before kidney transplant. Intervention 2: The control group will received oral plac
Prevention
The trial group will be administered oral melatonin at the dose of 3mg/day for a period of 28 days before kidney transplant.
The control group will received oral placebo at the dose of 3mg/day for a period of 28 days before kidney transplant.
Sponsors
Vice Chancellor for Research of Tabriz University of Medical Sciences, Biotechnology Research Center
Nephrology Research Center
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: kidney transplant candidate? had a history of dialysis at least 3 months. Exclusion criteria :Patients with inflammatory disease? acute or chronic infection? autoimmune diseases? hepatic insufficiency ? diabetes? malignancy ?depression ? high and low pressure ? seizures ? smokers
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TNF-a. Timepoint: 3 month. Method of measurement: ELISA.;Nulear NFKB activity. Timepoint: 3 month. Method of measurement: ELISA.;Oxidative stress factors. Timepoint: 3 month. Method of measurement: spectrophotometric methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| Klotho gene and protein expression. Timepoint: 3 month. Method of measurement: Real-time PCR and western blotting. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Hassan Argani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed